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Peripheral arterial disease (PAD) results from atherosclerosis that leads to blocked
arteries and reduced blood flow, most commonly in the arteries of the legs. PAD
clinical trials to induce angiogenesis to improve blood flow conducted in the last decade
have not succeeded. We have recently constructed PADPIN, protein-protein interaction
network (PIN) of PAD, and here we combine it with the drug-target relations to identify
potential drug targets for PAD. Specifically, the proteins in the PADPIN were classified
as belonging to the angiome, immunome, and arteriome, characterizing the processes
of angiogenesis, immune response/inflammation, and arteriogenesis, respectively. Using
the network-based approach we predict the candidate drugs for repositioning that have
potential applications to PAD. By compiling the drug information in two drug databases
DrugBank and PharmGKB, we predict FDA-approved drugs whose targets are the
proteins annotated as anti-angiogenic and pro-inflammatory, respectively. Examples of
pro-angiogenic drugs are carvedilol and urokinase. Examples of anti-inflammatory drugs
are ACE inhibitors and maraviroc. This is the first computational drug repositioning study
for PAD.
Keywords: peripheral arterial disease, computational drug repositioning, inflammation, angiogenesis, drug-target
network, bioinformatics, cardiovascular disease
Introduction
Recent pharmaceutical research and development (R&D) reports show that the probability of
success for a new pharmaceutical compound to get to the market has declined in the last 10 years
(Pammolli et al., 2011). The average time of drug development has increased from 9.7 years during
the 1990s to 13.9 years from 2000 onwards. The average probability of success of total numbers of
R&D projects in the cardiovascular system is only 4.86%. Drug repositioning, new use of old drugs,
can shorten the development time and provide solutions for the high cost and declined number
of new successful drugs of the pharmaceutical companies (Dudley et al., 2011). Computational
repositioning strategies can predict new therapeutic indications for FDA-approved drugs, which
then have to undergo clinical trials for the new indication (Belch et al., 2003; Ostchega et al., 2007;
Shameer et al., 2015). In this study, we primarily use the network-based approach in computational
drug repositioning.
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Peripheral arterial disease (PAD) results from atherosclerosis,
the plaque built-up inside the arteries, which blocks the blood
ﬂow in the peripheral arteries and most commonly in the arteries
that perfuse the legs (Belch et al., 2003; Annex, 2013). Age,
diabetes, and cigarette smoking are the major risk factors for
the development of PAD (Belch et al., 2003; Ostchega et al.,
2007; Annex, 2013). There are 8–12 million people with PAD
in the United States (Writing Group et al., 2010). The clinical
manifestations of PAD range from patients who do not report leg
pain but have a lower functional capacity (approximately 50% of
all PAD subjects) to patients who have intermittent claudication
manifested as leg pain with walking/exercise that is relieved with
rest (approximately 33–40% of all PAD subjects) (Hirsch et al.,
2006; Norgren et al., 2007). With the goal to increase blood ﬂow
around blockages, clinical trials using drugs and gene delivery
for therapeutic angiogenesis such as VEGF (vascular endothelial
growth factor) gene delivery have been performed for the last two
decades but have not been successful.
Hoier et al. showed that there was no diﬀerence in basal
skeletal muscle VEGF mRNA content before and after passive
or active exercise between PAD patients and control (Hoier
et al., 2013). However, the basal level of anti-angiogenic protein
thrombospondin-1 (TSP1) was remarkably higher in the PAD
patients than control groups. They conclude that the anti-
angiogenic factors dominate the pro-angiogenic factors in PAD
patients. The up-regulation of TSP1 has been shown in various
gene expression microarray studies of mouse (Chu et al., 2015)
and human samples of PAD (Fu et al., 2008; Masud et al., 2012).
Currently there are no FDA-approved drugs targeting TSP1.
Therefore, the computational drug repositioning approach to
predict the drugs targeting other endogenous anti-angiogenic
proteins should be helpful for designing clinical trials for
therapeutic angiogenesis in PAD.
Inﬂammation plays an important role in initiation and
progression of PAD, and many circulating biomarkers such
as matrix metalloproteinases (MMPs) and interleukin are
considered as the clinical manifestation of PAD (Signorelli
et al., 2014). Atherosclerosis is the dominant cause of many
cardiovascular diseases, including myocardial infarction, heart
failure, coronary artery disease (CAD), and stroke (Frostegård,
2013). Atherosclerosis is a chronic inﬂammatory condition.
Potential anti-inﬂammatory treatments in atherosclerosis
are reviewed in Frostegård (2013). The interplay between
inﬂammation and endothelial progenitor cells is critical in
cardiovascular diseases (Grisar et al., 2011). Combination of
anti-inﬂammatory and pro-angiogenic treatments for PAD
was suggested and validated in vivo by Zachman et al. (2014).
However, a systematic bioinformatics approach to identify the
potential drug repositioning for inhibition of anti-angiogenic
and pro-inﬂammatory proteins for PAD is still lacking.
We previously constructed the PADPIN, protein-protein
interaction network (PIN) in PAD that includes angiome,
immunome, and arteriome, characterizing the processes
of angiogenesis, immune response/inﬂammation and
arteriogenesis, respectively (Chu et al., 2015). We have analyzed
several available microarray gene expression datasets from
ischemic and non-ischemic muscles in two mouse models of
PAD (in C57BL/6 and BALB/c mouse species) from Hazarika
et al. (2013) to identify important genes/proteins in PAD, such as
THBS1 (thrombospondin-1), TLR4 (toll-like receptor 4), EphA4
(EPH receptor A4), and TSPAN7 (tetraspanin 7). However,
none of the four genes (THBS1, TLR4, EphA4, and TSPAN7)
have FDA-approved drugs to target them. Considering the time
(>10 years) and cost (>$1 billion) for developing a new drug
agent, drug repositioning in PAD oﬀers promise of providing
eﬀective therapeutics in shorter time and at lower cost compared
to conventional de-novo drug discovery and development. In
addition, drug repurposing is an approach of taking agents
in development that have achieved adequate safety for one
indication but are tested for eﬃcacy in another when safety is
already evident.
Materials and Methods
Resources for Drugs and Drug-target
Interactions
We rely on two major resources for drug information and
drug-target, DrugBank 3.0 http://www.drugbank.ca/ (Knox
et al., 2011) and Pharmacogenomics Knowledge Base
(PharmGKB) http://www.pharmgkb.org/ (Whirl-Carrillo
et al., 2012). DrugBank contains extensive omics data,
such as pharmacogenomic, pharmacoproteomic, and
pharmacometabolomic data. We use DTome (Drug-Target
interactome tool) (Sun et al., 2012) to compile all the drugs
included in DrugBank 3.0 (Knox et al., 2011), including the
approved, experimental, nutraceutical, illicit, and withdrawn
drugs. We compile three binary relations in DrugBank from
DTome: drug-drug, drug-gene, and drug-target interactions.
This compilation provides the rich resources for the potential
repositioning or repurposing. By considering the drug safety
and development time, we focus on FDA-approved drugs in this
study. We compiled the three binary relations from PharmGKB:
gene-disease, gene-drug, and gene-gene interactions. The drug-
target interactions were compiled from both DrugBank (Knox
et al., 2011) and PharmGKB (Whirl-Carrillo et al., 2012).
Proteins in PADPIN and Therapeutic
Angiogenesis in PAD
Details of the construction of PADPIN, protein-protein
interaction (PIN) of PAD in angiogenesis, immune response
and arteriogenesis, are described in Chu et al. (2015). The
methodology is similar to that used for constructing the global
PIN of angiogenesis (angiome) that comprises 1233 proteins
and 5726 interactions (Chu et al., 2012). The PIN of immune
response (immunome) comprises 3490 proteins and 21,164
interactions. The PIN of arteriogenesis (arteriome) comprises
289 proteins and 803 interactions. The degree of node represents
the number of links to a node in the network. The network
parameter was calculated by NetworkAnalyzer (Assenov et al.,
2008) in Cytoscape (Smoot et al., 2011). We start with the
genes listed in the three PINs, to ﬁnd the interactive drugs from
the DrugBank and PharmGKB. Note that in bioinformatics
publications, and speciﬁcally in protein-protein networks
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publications, the terms “gene” and “protein” are sometimes used
interchangeably; while we mostly use “protein” term in this
context, we sometime use “gene” to be consistent with previous
publications.
List of Anti-angiogenic and Pro-inflammatory
Genes
The activation of a speciﬁc biological process can be implemented
using two strategies. One is direct activation of the genes
involved in positive regulation of that biological process; the
other is inhibition of the genes involved in negative regulation
of that biological process. Speciﬁcally for PAD, to stimulate
vascular growth and remodeling and increase the blood ﬂow,
we propose inhibition of genes annotated as negative regulation
of angiogenesis as a therapeutic approach to stimulating
angiogenesis. The rationale for this approach is that numerous
clinical trials aimed at stimulating angiogenesis by growth factors
such as VEGF-A and FGF-2 have not been successful. We
identiﬁed 39 anti-angiogenic genes, chosen by Gene Ontology
(GO: 0016525) and literature (Chu et al., 2014). The endothelial
dysfunction in patients with PAD is characterized by impaired
nitric oxide signaling, excessive inﬂammation and diminished
response to angiogenic factors (Annex, 2013). To inhibit
the inﬂammation, we propose inhibition of pro-inﬂammatory
responses as a therapeutic approach for anti-inﬂammatory
treatment of PAD. There are 89 genes classiﬁed in positive
regulation of inﬂammatory response (GO:0050729).We list these
genes in Table 1.
Results
Drug-targets Relations in Angiome, Immunome
and Arteriome of PADPIN
We collected 11,043 binary relations between the drug and
drug targets from DrugBank 3.0 (Knox et al., 2011) and 3138
binary relations between the drug and associated genes of that
drug, which may not be the direct targets, from PharmGKB
(Whirl-Carrillo et al., 2012). By matching the genes in angiome,
immunome, and arteriome with the drug targets listed in the
drug-gene binary relations from DrugBank and PharmGKB,
we build the complete tables of genes and repositioning drugs
(Tables S1–S3). Table S1 shows 409 and 174 drug targets listed
in angiome for the drugs from DrugBank and PharmGKB,
respectively. We select the genes with at least one drug targeting
that gene in angiome, and skip the genes without any drug-gene
relations. There might be multiple drugs targeting the same drug
target; we list the multiple drugs in the same row of the table.
Table S2 shows 865 and 382 drug targets in immunome for the
drugs from DrugBank and PharmGKB, respectively. Table S3
shows 82 and 46 drug targets in arteriome for the drugs from
DrugBank and PharmGKB, respectively.
We rank the genes in angiome, immunome, and arteriome
by the degree of nodes, i.e., number of links of the nodes
in the network, in Tables S1–S3, respectively. Tables S1–S3
provide the complete list of drugs and drug targets which are
annotated in angiogenesis, immune response/inﬂammation, and
arteriogenesis. Tables S1–S3 provide the complete list of drugs
in DrugBank and PharmGKB, including approved, experimental,
nutraceutical, illicit, and withdrawn drugs. Considering the drug
safety and eﬃcacy issues, we mostly consider the FDA-approved
drugs in the predictions of repositioning drugs (Table S4).
Inhibition of Anti-angiogenic Pro-inflammatory
Genes
We postulate two strategies to the PAD treatment: pro-
angiogenic and anti-inﬂammatory. Starting from the 39 genes
annotated in negative regulation of angiogenesis (see Materials
and Methods), we match the genes with drug targets and drugs
listed in Table S1, and only list the FDA-approved drugs from
DrugBank in Table 2. The ﬁve genes are CCL2, NPPB, NPR1,
PF4, and SERPINE1. These drugs include mimosine targeting
CCL2, carvedilol targeting NPPB, nitroprusside targeting NPR1,
urokinase, reteplase, and drotrecogin alfa targeting SERPINE1.
The beta-blockers (e.g., carvedilol in our prediction) in general
have not been shown to aﬀect PAD symptoms, but they
do not make PAD symptoms worse (Paravastu et al., 2013).
Infusion of recombinant-based plasminogen activator (e.g.,
reteplase) and urokinase can clear blood clots and restore blood
TABLE 1 | List of 39 anti-angiogenic and 89 pro-inflammatory genes.
Categories Gene ontology List of genes
Anti-angiogenic Negative regulation of angiogenesis (GO: 0016525) AMOT, ANGPT2, APOH, BAI1, CCL2, CCR2, COL4A2, COL4A3, CXCL10, FASLG,
FOXO4, GHRL, GTF2I, HDAC5, HHEX, HOXA5, HRG, KLF4, KLK3, KRIT1, LECT1, LIF,
MAP2K5, NF1, NPPB, NPR1, PDE3B, PF4, PML, PTPRM, ROCK1, ROCK2,
SERPINE1, SERPINF1, STAB1, THBS1, THBS2, THBS4, TIE1
Pro-inflammatory Positive regulation of inflammatory response
(GO:0050729)
ACE, ADAM8, ADORA2B, ADORA3, AGER, AGT, AGTR1, ALOX5AP, AOC3, C3,
CCL24, CCL3, CCL3L3, CCL5, CCR2, CCR5, CCR7, CD28, CD47, CLOCK, CNR1,
CTSS, CX3CL1, EDNRA, EGFR, FABP4, FCER1A, FCER1G, FCGR1A, FCGR2A,
FFAR3, GPRC5B, HSPD1, HYAL2, IDO1, IL12B, IL15, IL18, IL1B, IL1RL1, IL2, IL21,
IL23A, IL33, IL6, IL6ST, ITGA2, JAK2, LBP, LTA, MAPK13, MIF, NLRP12, NPY5R,
OSM, OSMR, PDE2A, PDE5A, PIK3CG, PLA2G2A, PLA2G4A, PLA2G7, PRKCA,
PTGER3, PTGER4, PTGS2, RPS19, S100A12, S100A8, S100A9, SERPINE1, STAT5A,
STAT5B, TAC1, TGM2, TLR2, TLR3, TLR4, TLR7, TLR9, TLR10, TNF, TNFRSF11A,
TNFRSF1A, TNFSF11, TNFSF4, TNIP1, WNT5A, ZP3
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TABLE 2 | Predictions of pro-angiogenic FDA-approved drugs that target anti-angiogenic genes.
Gene symbol Gene name DrugBank Physiological relevance in PAD or CAD
CCL2 Chemokine (C-C motif) ligand 2 Mimosine, danazol Potential indicator of atherosclerosis in PAD
(Rull et al., 2011)
NPPB Natriuretic peptide B Carvedilol Three SNPs at NPPB locus associated with
lower risk of PAD (Hu et al., 2013)
NPR1 Natriuretic peptide receptor 1 Nitroprusside, nitroglycerin, isosorbide dinitrate,
amyl nitrite, erythrityl tetranitrate, nesiritide
PF4 Platelet factor 4 Drotrecogin alfa PF4 level increasing in patients with coronary
artery ectasia (Yasar et al., 2007)
SERPINE1 Serpin peptidase inhibitor, clade E (nexin,
plasminogen activator inhibitor type 1), member 1
Alteplase, urokinase, reteplase, anistreplase,
tenecteplase, drotrecogin alfa
Plasminogen activator inhibitor-1 (PAI-1)
increasing in patients with CLI (critical limb
ischemia), leading to prothrombotic (Björck
et al., 2013)
ﬂow in occluded blood vessels of patients with diseases such
as myocardial infarction and PAD (Lippi et al., 2013). The
mechanism of mimosine targeting CCL2 in PAD is not clear.
These anti-angiogenic proteins may not have direct
physiological relevance in PAD. We use PubMed by searching
the keywords “(Gene symbol) AND (PAD OR coronary arterial
disease)” to ﬁnd the relevant literature in the recent 10 years
(2005–2015) for the ﬁve genes in PAD. These references
support the potential biomarkers or drug targets of the ﬁve
anti-angiogenic proteins in PAD, such as CCL2 (Rull et al.,
2011), NPPB (Hu et al., 2013), and SERPINE1 (Yasar et al.,
2007). However, these references do not link the anti-angiogenic
properties of these genes to PAD. Thus, the concept of inhibition
of anti-angiogenic proteins in PAD is novel and should be further
explored.
Inhibition of Pro-inflammatory Genes
We match the 89 pro-inﬂammatory genes with drug targets and
drugs listed in Table S2, and only list the FDA-approved drugs
fromDrugBank inTable 3 (see the list of pro-inﬂammatory genes
in Methods). The corresponding FDA-approved drugs include
maraviroc (an antiretroviral drug, a CCR5 inhibitor), bosentan (a
dual endothelin receptor antagonist that aﬀects both endothelin
A and B receptors, used in the treatment of pulmonary artery
hypertension), sitaxentan (endothelin A receptor antagonist,
used in the treatment of pulmonary artery hypertension),
cetuximab (EGFR antagonist, used in several types of cancer)
and imiquimod (an immune response modulator, used for skin
diseases including skin cancer).
To ﬁnd the physiological relevance of these pro-inﬂammatory
genes in PAD, we continue to use PubMed to ﬁnd the relevant
references. References in Table 3 support our hypothesis that
anti-inﬂammatory drugs have high potential for repositioning
for PAD. Some drugs cannot improve ABI (ankle-pressure
index) of PAD patients but can improve the walking ability
in patients with critical limb ischemia (CLI), such as ACE
inhibitors (Hunter et al., 2013; Shahin et al., 2013). Some genes
are indicated as related with PAD, such as C3 (complement
component 3) (Fehervari et al., 2014), PTGS2 (prostaglandin-
endoperoxide synthase 2) (Flórez et al., 2009), SERPINE1
(Björck et al., 2013), S100A12 (Shiotsu et al., 2011), and
TNF (Botti et al., 2012; Wozniak et al., 2012; Gardner et al.,
2014). Some genes are potential biomarkers or associated with
other cardiovascular diseases, such as AGTR1 (angiotensin II
receptor, type 1) in coronary occlusive disease (Baños et al.,
2011), CCR5 in pulmonary arterial hypertension (Amsellem
et al., 2014), LTA (lymphotoxin alpha) in CAD (Topol et al.,
2006), and PRKCA (protein kinase C, alpha) in atherosclerosis
(Konopatskaya and Poole, 2010). Many of the anti-inﬂammatory
genes in Table 3 are not directly associated with PAD or CAD
based on PubMed search, such as ADORA2B (adenosine A2b
receptor), EDNRA (endothelin receptor type A), FCER1G (Fc
receptor, IgE, high aﬃnity I, gamma polypeptide), STAT5B
(signal transducer and activator of transcription 5B), and TLR9
(toll-like receptor 9). In general, the physiological evidence of
these anti-inﬂammatory genes listed in Table 3 strongly supports
our hypothesis that inhibition of pro-inﬂammatory genes is a
viable drug repositioning strategy in PAD.
Visualization of Drug-target Network
Graph representation is used to visualize pro-angiogenic and
anti-inﬂammatory repositioning drugs for PAD in Figures 1, 2,
respectively. We plot the drug-target networks of the anti-
angiogenic and pro-inﬂammatory proteins for the drugs in
Tables 2, 3, respectively. We represent the drug target by pink
circle and the drug by blue square. Figure 1 shows several
compounds targeting the proteins which are annotated as
negative regulation of angiogenesis. Figure 2 shows the drug-
target networks of the anti-inﬂammatory drugs and targets from
Table 3. The number of inﬂammation targets and drugs in
Figure 2 is much larger than anti-angiogenic targets and drugs
in Figure 1. This gives the insight for the development of clinical
trials of anti-inﬂammatory drugs in PAD in the future. We will
discuss the potential clinical trials in Discussion.
Discussion
The clinical trials aimed at stimulating VEGF in PAD and
CAD have been unsuccessful (Annex, 2013). The exercise
therapy has been demonstrated as the beneﬁcial treatment
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TABLE 3 | Predictions of anti-inflammatory FDA-approved drugs that target pro-inflammatory genes.
Gene
symbol
Description DrugBank Physiological relevance in PAD or CAD
ACE Angiotensin I converting enzyme Ramipril, fosinopril, trandolapril, benazepril,
enalapril, candoxatril, moexipril, lisinopril,
perindopril, quinapril, rescinnamine, captopril,
cilazapril, spirapril
ACE inhibitor helping the walking ability in
patients with CLI, but not improving ABI
(ankle-pressure index) (Hunter et al., 2013;
Shahin et al., 2013)
ADORA2B Adenosine A2b receptor Theophylline, adenosine, enprofylline,
defibrotide
AGTR1 Angiotensin II receptor, type 1 Valsartan, olmesartan, losartan, candesartan,
eprosartan, telmisartan, irbesartan, forasartan,
saprisartan, tasosartan
Correlation between the increased AGTR1
and cardiovascular risk factors (Baños
et al., 2011)
AOC3 Amine oxidase, copper containing 3 Phenelzine, hydralazine
C3 Complement component 3 Intravenous immunoglobulin C3 level in serum associated with ABI and
atherosclerosis in PAD patients (Fehervari
et al., 2014)
CCR5 Chemokine (C-C motif) receptor 5 Maraviroc A treatment target in pulmonary arterial
hypertension (Amsellem et al., 2014)
CNR1 Cannabinoid receptor 1 (brain) Dronabinol, nabilone, rimonabant, dronabinol
EDNRA Endothelin receptor type A Bosentan, sitaxentan
EGFR Epidermal growth factor receptor Cetuximab, trastuzumab, lidocaine, gefitinib,
erlotinib, lapatinib, panitumumab
FCER1A Fc fragment of IgE, high affinity I, receptor for; alpha
polypeptide
Omalizumab, benzylpenicilloyl polylysine
FCER1G Fc receptor, IgE, high affinity I, gamma polypeptide Benzylpenicilloyl polylysine















IL1B Interleukin 1, beta Minocycline, gallium nitrate, canakinumab
IL6 Interleukin 6 Ginseng Phase III clinical trial targeting IL-6 by
tocilizumab in cardiovascular disease
(Ridker and Lüscher, 2014)
LTA Lymphotoxin alpha Etanercept Implicated in predisposition for heart
attack by genome-wide association
studies (GWAS) (Topol et al., 2006)
(Continued)
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TABLE 3 | Continued
Gene
symbol
Description DrugBank Physiological relevance in PAD or CAD





PLA2G2A Phospholipase A2, group IIA (platelets, synovial fluid) Indomethacin, diclofenac, ginkgo biloba,
suramin, ginkgo biloba
PLA2G4A Phospholipase A2, group IVA (cytosolic,
calcium-dependent)
Fluticasone propionate, quinacrine
PRKCA Protein kinase C, alpha Phosphatidylserine, vitamin E The key protein in regulation of platelet
function and thrombosis in arteries
(Konopatskaya and Poole, 2010)
PTGER3 Prostaglandin E receptor 3 (subtype EP3) Bimatoprost, dinoprostone, misoprostol
PTGS2 Prostaglandin-endoperoxide synthase 2




ketorolac, tenoxicam, lenalidomide, celecoxib,
tolmetin, piroxicam, fenoprofen, diclofenac,
sulindac, flurbiprofen, etodolac, mefenamic
acid, naproxen, sulfasalazine, phenylbutazone,
meloxicam, carprofen, diflunisal, suprofen,
salicyclic acid, meclofenamic acid,
acetylsalicylic acid, bromfenac, oxaprozin,








PTGS2 (COX2) inhibition improves
inflammation and endothelial dysfunction
in PAD patients with intermittent
claudication (IC) (Flórez et al., 2009)
S100A12 S100 calcium binding protein A12 Olopatadine, amlexanox The potential biomarker for chronic arterial
disease (Saito et al., 2012) and associated
with PAD (Shiotsu et al., 2011)
SERPINE1 Serpin peptidase inhibitor, clade E (nexin,
plasminogen activator inhibitor type 1), member 1
Alteplase, urokinase, reteplase, anistreplase,
tenecteplase, drotrecogin alfa
Level of plasminogen activator inhibitor-1
(PAI-1) increased in patients with CLI
(critical limb ischemia) (Björck et al., 2013)
STAT5B Signal transducer and activator of transcription 5B Dasatinib
TLR2 Toll-like receptor 2 Ospa lipoprotein TLR2 and TLR4 expression increase
during atherosclerosis, but only TLR4
gene expression associated with PAD
(Varela et al., 2015)
TLR7 Toll-like receptor 7 Imiquimod, hydroxychloroquine
TLR9 Toll-like receptor 9 Chloroquine, hydroxychloroquine
TNF Tumor necrosis factor Etanercept, adalimumab, infliximab,
chloroquine, thalidomide, glucosamine,
clenbuterol, pranlukast, amrinone, thalidomide
Circulating TNF higher in PAD patients
than control (Gardner et al., 2014);
Circulating cytokines induce endothelial
dysfunction in PAD patients (Botti et al.,
2012); Negative correlation between TNF
concentration and pain free walking
distance (Wozniak et al., 2012)
TNFSF11 Tumor necrosis factor (ligand) superfamily,
member 11
Lenalidomide
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FIGURE 1 | Pro-angiogenic drug-target interaction networks.
FIGURE 2 | Anti-inflammatory drug-target interaction networks.
for PAD, including walking tolerance, modiﬁed inﬂammatory
markers, and adaptation of the limb (e.g., angiogenesis and
arteriogenesis) (Haas et al., 2017). Clinical trials with agents
targeting angiogenesis and inﬂammation, other than stimulation
of VEGF, should be considered in the future. Below we provide
insights for the potential repositioning drugs in PAD identiﬁed
in this study, including the mechanism of action of these drugs,
case studies for several selected drugs in clinical trials, and future
experimental validations.
Mechanism of Action of Repositioning Drugs for
PAD
Tables 1, 2 provide the anti-angiogenic and pro-inﬂammatory
genes/proteins, drugs targeting these molecules, and
physiological evidence for the involvement of these molecules
in PAD. However, even though these drug-targets have been
identiﬁed by our bioinformatics approaches, the mechanism
of action of these drugs in PAD and the feasibility of the
clinical trials need to be elucidated. Speciﬁcally, the eﬀect
of some of these drugs to promote angiogenesis in PAD by
targeting anti-angiogenic proteins is unknown. Therefore,
we search PubMed for the drugs listed in Table 2 using the
keywords “(drug name) AND angiogenesis” to understand
the mechanism and original use of these putative pro-
angiogenic drugs. We list the drugs with at least one
supporting reference found in PubMed in Table 4. These
drugs include beta-1 adrenergic receptors blocker (carvedilol,
targeting NPPB), vasodilator (isosorbide dinitrate, targeting
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TABLE 4 | Mechanism of Action and original use of the drugs for repositioning as pro-angiogenic in PAD.
Drug name Target in Degree of target Mechanism of action Original use PubMed search
angiogenesis in angiome
Alteplase SERPINE1 14 Plasminogen activator Acute ischemic stroke Lapchak and Araujo, 2007;
Hacke et al., 2008
Danazol CCL2 12 Synthetic steroid with antigonadotropic and
anti-estrogenic activities
Endometriosis Thomas et al., 2007; Szubert
et al., 2014
Nitroprusside NPR1 4 A source of nitric oxide, a potent peripheral
vasodilator
Hypertensive emergency Ziche et al., 1994; Pyriochou
et al., 2007
Isosorbide dinitrate NPR1 4 Vasodilator Angina pectoris Goertz et al., 2011
Nesiritide NPR1 4 Recombinant form of brain natriuretic peptide Heart failure Shmilovich et al., 2009
Carvedilol NPPB 3 Beta-1 and beta-2 adrenergic receptors
blocker
Congestive heart failure Le et al., 2013; Stati et al., 2014
NPR1), and plasminogen activator (alteplase, targeting
SERPINE1).
We further search PubMed for the anti-inﬂammatory drugs in
Table 3 using the keywords “(drug name) AND inﬂammation”
to elucidate the mechanism and original use of these anti-
inﬂammatory drugs (Table 5). These drugs include antiplatelet
(abciximab targeting FCGR1A, acetylsalicylic acid targeting
PTGS2), monoclonal antibody (adalimumab targeintg TNF-
alpha), immune suppressant (alefacept targeting FCGR1A and
FCGR2A), ACE inhibitor (benazepril, captopril and enalapril),
non-steroidal anti-inﬂammatory drug (NSAID, e.g., bromfenac,
celecoxib, diclofenac, ketorolac, nepafenac, sulindac), and PDE5
inhibitor (tadalaﬁl, vardenaﬁl).
Case Studies of Potential Drug Targets and Drug
Repositioning in PAD
We choose three candidate drugs for repositioning in PAD as
case studies of our predictions. We selected several drugs that are
anti-inﬂammatory or pro-angiogenic and had no eﬀects on each
other. These drugs include bosentan, carvedilol, and maraviroc.
We compared the drug targets with the up-regulated genes in the
microarray dataset of PAD, including the mouse data of Hazarika
et al. (2013), and human microarray studies of Masud et al.
(2012), Fu et al. (2008), and Croner et al. (2012).
Case I: Bosentan Targeting EDNRA
The endothelin receptor antagonists (bosentan and ambrisentan)
have been approved for use in pulmonary arterial hypertension
(PAH) and have been assigned orphan drug status. Details of
hepatotoxicity of bosentan, ambrisentan, and sitaxentan are
reviewed in de Haro Miralles et al. (2010). Endothelin-1 is
a powerful endogenous vasoconstrictor (Frumkin, 2012) and
thus blocking endothelin could improve perfusion to the lower
extremities in patients with PAD. In a pre-clinical PAD model,
Luyt et al. (2000) demonstrated that endothelin, antagonists,
bosentan, and darusentan (LU13525) increased tissue blood ﬂow
measured by laser Doppler perfusion imaging. de Haro Miralles
et al. (2010) examined plasma levels of endothelin and showed
that endothelin levels were increased in patients with intermittent
claudication compared to non-PAD controls. Just as importantly
patients with the most severe form of PAD, CLI, did not
demonstrate elevated levels of endothelin, which suggests that
an elevation of endothelin is speciﬁc to the pathophysiology of
intermittent claudication and not all forms of PAD. The original
indication of zibotentan was in oncology and pulmonary artery
hypertension. The reuse of an endothelin receptor antagonists in
PAD patients with intermittent claudication is now in a Phase
II clinical trial; the details of the clinical trial of zibotentan are
provided in ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/
NCT01890135?term=NCT01890135&rank=1.
Case II: Carvedilol Targeting NPPB
Carvedilol has anti-inﬂammatory and pro-angiogenic eﬀects
in chronic ischemic cardiomyopathy (Le et al., 2013).
Carvedilol showed improvement of myocardial ﬂow and
reduction of inﬂammation in the canine model of multivessel
cardiomyopathy. The anti-inﬂammatory cytokine IL-10, which
inhibits inﬂammatory cytokines such as TNFα, IL-1, IL-6, IL-8,
and IL-12, was up-regulated in the carvedilol-treated animals.
In the PAD microarray data, the inﬂammatory cytokine IL-8
was up-regulated as found in Masud et al. (2012) and Croner
et al. (2012). Though beta-blockers are commonly used in
patients with PAD, currently there are no speciﬁc clinical trials
for carvedilol being compared to placebo or other beta-blockers
in PAD patients.
Case III: Maraviroc Targeting CCR5
Maraviroc is an HIV drug targeting CCR5, which is involved
in the inﬂammation pathway (Francisci et al., 2014). Therefore,
maraviroc could have anti-inﬂammatory and anti-atherosclerosis
eﬀects, and become a potential repositioning drug in PAD.
Croner et al. (2012) show the up-regulation of CCR5 in
microarrays from the human femoral artery in PAD. CCR5
inhibitor maraviroc also blocks cell migration andmetastasis, but
not directly aﬀects the angiogenesis pathway in triple negative
breast cancer cell lines (Lee et al., 2014). Currently there are no
clinical trials for maraviroc in PAD patients.
Limitations of Computational Drug Repositioning
Approaches
There are several limitations by the computational approaches
to predict the repositioning drugs in PAD. First, PAD is a
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complex disease caused by many risk factors and classiﬁed
by diﬀerent stages of diseases. Our methods cannot predict
the repositioning drugs based on various conditions in PAD
patients. Second, the current available clinical trials based on
these predicted repositioning drugs in PAD patients are very
limited. The available gene expression dataset in human PAD
and mouse PAD model is limited. It is diﬃcult to validate our
predictions by current clinical trials and available microarray
data. Third, the pro-angiogenic and anti-inﬂammatory drug-
target networks cannot directly link the drugs to PAD based
on the current physiological evidence in PAD. The value of the
computational drug repositioning might be limited for clinical
trial design.
Conclusions
Our study provides comprehensive predictions of potential pro-
angiogenic and anti-inﬂammatory drugs and drug targets for
PAD patients. Based on the protein-protein interaction network
PADPIN, we collected the binary relations between FDA-
approved drugs and genes annotated in PADPIN. By gathering
FDA-approved drugs, these predictions form a basis for further
validation and future translational research in PAD.
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